A new small molecule could treat and prevent excess bone formation. Fibrodysplasia ossificans progressiva (FOP) is an extremely rare disease estimated to affect about one in 2 million people worldwide ...
Researchers show how damaged tissue is reshaped to trigger painful bone formation in muscles and tendons CHINA, ...
Proposed model for Regulation of BMP Activity by DDR2. After binding collagen, DDR2 alone or together with collagen-binding β1 integrins stabilizes YAP/TAZ nuclear accumulation. This is accomplished ...
Bone regeneration research has taken a significant leap forward with the discovery of a crucial mechanism that could transform treatments for bone disorders. Scientists have identified how Discoidin ...
FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approve ...
A research team led by Associate Professor Makoto Ikeya in the Department of Clinical Application at Kyoto University has developed a promising new therapeutic strategy for fibrodysplasia ossificans ...
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation Garetosmab is the first and only treatment to demonstrate a dramatic ...
Drug trial shows reduced abnormal bone formation in those with fibrodysplasia ossificans progressiva
A multisite, international phase 2 trial evaluating the investigational drug garetosmab has shown that it reduced soft-tissue flare-ups significantly and prevented new areas of abnormal bone formation ...
Garetosmab is a fully-human monoclonal antibody designed to bind and neutralize Activin A, a major promoter of heterotopic ossification in patients with FOP.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results